Matthew R Smith1, Fred Saad2, Dana E Rathkopf3, Peter F A Mulders4, Johann S de Bono5, Eric J Small6, Neal D Shore7, Karim Fizazi8, Thian Kheoh9, Jinhui Li10, Peter De Porre11, Mary B Todd12, Margaret K Yu13, Charles J Ryan6. 1. Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA. Electronic address: smith.matthew@mgh.harvard.edu. 2. University of Montréal, Montréal, Québec, Canada. 3. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York, NY, USA. 4. Radboud University Medical Centre, Nijmegen, The Netherlands. 5. The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK. 6. Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA. 7. Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA. 8. Institut Gustave Roussy, University of Paris Sud, Villejuif, France. 9. Janssen Research & Development, San Diego, CA, USA. 10. Johnson & Johnson Medical China, Shanghai, China. 11. Janssen Research & Development, Beerse, Belgium. 12. Janssen Global Services, Raritan, NJ, USA. 13. Janssen Research & Development, Los Angeles, CA, USA.
Abstract
In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus prednisone in patients with mCRPC. We investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone (55 patients) and enzalutamide (33 patients) in a post hoc analysis of COU-AA-302. Prostate-specific antigen (PSA) response was assessed. Median time to PSA progression was estimated using the Kaplan-Meier method. The PSA response rate (≥50% PSA decline, unconfirmed) was 44% and 67%, respectively. The median time to PSA progression was 3.9 mo (range 2.6-not estimable) for subsequent abiraterone acetate plus prednisone and 2.8 mo (range 1.8-not estimable) for subsequent enzalutamide. The majority of patients (68%) received intervening chemotherapy before subsequent abiraterone acetate plus prednisone or enzalutamide. While acknowledging the limitations of post hoc analyses and high censoring (>75%) in both treatment groups, these results suggest that subsequent therapy with abiraterone acetate plus prednisone or enzalutamide for patients who progressed on abiraterone acetate is associated with limited clinical benefit. PATIENT SUMMARY: This analysis showed limited clinical benefit for subsequent abiraterone acetate plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer following initial treatment with abiraterone acetate plus prednisone. This analysis does not support prioritization of subsequent abiraterone acetate plus prednisone or enzalutamide following initial therapy with abiraterone acetate plus prednisone.
In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus prednisone in patients with mCRPC. We investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone (55 patients) and enzalutamide (33 patients) in a post hoc analysis of COU-AA-302. Prostate-specific antigen (PSA) response was assessed. Median time to PSA progression was estimated using the Kaplan-Meier method. The PSA response rate (≥50% PSA decline, unconfirmed) was 44% and 67%, respectively. The median time to PSA progression was 3.9 mo (range 2.6-not estimable) for subsequent abiraterone acetate plus prednisone and 2.8 mo (range 1.8-not estimable) for subsequent enzalutamide. The majority of patients (68%) received intervening chemotherapy before subsequent abiraterone acetate plus prednisone or enzalutamide. While acknowledging the limitations of post hoc analyses and high censoring (>75%) in both treatment groups, these results suggest that subsequent therapy with abiraterone acetate plus prednisone or enzalutamide for patients who progressed on abiraterone acetate is associated with limited clinical benefit. PATIENT SUMMARY: This analysis showed limited clinical benefit for subsequent abiraterone acetate plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer following initial treatment with abiraterone acetate plus prednisone. This analysis does not support prioritization of subsequent abiraterone acetate plus prednisone or enzalutamide following initial therapy with abiraterone acetate plus prednisone.
Authors: Benjamin A Teply; Hao Wang; Brandon Luber; Rana Sullivan; Irina Rifkind; Ashley Bruns; Avery Spitz; Morgan DeCarli; Victoria Sinibaldi; Caroline F Pratz; Changxue Lu; John L Silberstein; Jun Luo; Michael T Schweizer; Charles G Drake; Michael A Carducci; Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Samuel R Denmeade Journal: Lancet Oncol Date: 2017-12-14 Impact factor: 41.316
Authors: Fernando Cotait Maluf; Felipe Moraes Toledo Pereira; Adriano Gonçalves Silva; Aldo Lourenço Abbade Dettino; Ana Paula Garcia Cardoso; André Seeke Sasse; Andrey Soares; Ariel Galapo Kann; Daniel Herchenhorn; Denis Leonardo Fontes Jardim; Diego Emilio Lopera Cortés; Fábio Roberto Kater; Igor A Protzner Morbeck; João Francisco Navarro Reolon; José Augusto Rinck; Juan Jose Zarbá; Juan Pablo Sade; Karine Martins da Trindade; Leonardo Atem G A Costa; Lucas V Dos Santos; Manuel Caitano Maia; Mariana Bruno Siqueira; Silke Gillessen Journal: JCO Glob Oncol Date: 2021-04
Authors: J Cassinello; J Á Arranz; J M Piulats; A Sánchez; B Pérez-Valderrama; B Mellado; M Á Climent; D Olmos; J Carles; M Lázaro Journal: Clin Transl Oncol Date: 2017-11-13 Impact factor: 3.405
Authors: Daniel J George; Neeraj Agarwal; Oliver Sartor; Cora N Sternberg; Bertrand Tombal; Fred Saad; Kurt Miller; Niculae Constantinovici; Helen Guo; John Reeves; XiaoLong Jiao; Per Sandström; Frank Verholen; Celestia S Higano; Neal Shore Journal: Prostate Cancer Prostatic Dis Date: 2022-02-21 Impact factor: 5.455
Authors: Samuel R Denmeade; Hao Wang; Neeraj Agarwal; David C Smith; Michael T Schweizer; Mark N Stein; Vasileios Assikis; Przemyslaw W Twardowski; Thomas W Flaig; Russell Z Szmulewitz; Jeffrey M Holzbeierlein; Ralph J Hauke; Guru Sonpavde; Jorge A Garcia; Arif Hussain; Oliver Sartor; Shifeng Mao; Harry Cao; Wei Fu; Ting Wang; Rehab Abdallah; Su Jin Lim; Vanessa Bolejack; Channing J Paller; Michael A Carducci; Mark C Markowski; Mario A Eisenberger; Emmanuel S Antonarakis Journal: J Clin Oncol Date: 2021-02-22 Impact factor: 44.544